CC-99712 for Multiple Myeloma

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Celgene

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing a new drug, CC-99712, alone or with another drug, BMS-986405, in patients with a type of blood cancer that has come back and doesn't respond to usual treatments. Researchers will gradually find the safest and most effective amount while checking for side effects and cancer treatment effectiveness.

Eligibility Criteria

This trial is for adults over 18 with multiple myeloma that has come back or hasn't responded to treatment. They must have measurable disease and be in good physical condition (ECOG PS of 0 or 1). It's not for pregnant women, those with HIV, brain involvement of MM, recent stem cell transplants, or active hepatitis B/C.

Inclusion Criteria

I am 18 years old or older.

My multiple myeloma has come back or is not responding to treatment.

I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

I am HIV positive.

I had a stem cell transplant less than 6 months ago or am on medication for graft-versus-host disease.

I have an active hepatitis B or C infection.

I had a stem cell transplant using my own cells less than 3 months ago.

My multiple myeloma has affected my brain or spinal cord.

Treatment Details

The study tests CC-99712 alone or with BMS-986405 on participants with relapsed/refractory multiple myeloma. Part A finds the highest dose they can give without bad side effects (MTD) and Part B checks how well it works at this dose.

2Treatment groups

Experimental Treatment

Group I: Arm 2 (CC-99712 and BMS-986405 combination)Experimental Treatment2 Interventions

CC-99712 will be administered via IV infusion. BMS-986405 will be administered orally.

Group II: Arm 1 (CC-99712 monotherapy)Experimental Treatment1 Intervention

CC-99712 will be administered via intravenous (IV) infusion.